BREO ELLIPTA

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   May 10, 2013

   13 yr 4 mo ago

2. Exclusivity ends · NPP

   New patient population exclusivity (3 years)

   May 13, 2026

   1 mo ago

3. Today

4. Exclusivity ends · PED

   Pediatric exclusivity (adds 6 months)

   Nov 13, 2026

   in 5 mo

5. Patent 8511304 expires

   Listed drug product patent expiration.

   Jun 14, 2027

   in 1 yr

6. Patent 8511304 expires

   Listed drug product patent expiration.

   Jun 14, 2027

   in 1 yr

7. Patent 8511304 expires

   Listed drug product patent expiration.

   Jun 14, 2027

   in 1 yr

8. Patent 8511304*PED expires

   Listed listed patent expiration.

   Dec 14, 2027

   in 1 yr 6 mo

9. Patent 11116721 expires

   Listed drug product patent expiration.

   Feb 26, 2029

   in 2 yr 9 mo

10. Patent 11116721 expires

    Listed drug product patent expiration.

    Feb 26, 2029

    in 2 yr 9 mo

11. Patent 11116721 expires

    Listed drug product patent expiration.

    Feb 26, 2029

    in 2 yr 9 mo

12. Patent 11116721*PED expires

    Listed listed patent expiration.

    Aug 26, 2029

    in 3 yr 3 mo

13. Patent 8534281 expires

    Listed drug product patent expiration.

    Mar 08, 2030

    in 3 yr 9 mo

14. Patent 8534281*PED expires

    Listed listed patent expiration.

    Sep 08, 2030

    in 4 yr 3 mo

15. Patent 8746242 expires

    Listed drug product patent expiration.

    Oct 11, 2030

    in 4 yr 5 mo

16. Patent 8746242*PED expires

    Listed listed patent expiration.

    Apr 11, 2031

    in 4 yr 11 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NPPNew patient population exclusivity (3 years)

  May 13, 2026

  1 mo ago

• PEDPediatric exclusivity (adds 6 months)

  Nov 13, 2026

  in 5 mo

Listed patents (12)